Entera Announces Second Quarter 2026 Financial Results and Business Updates
Entera Bio Ltd. announced key updates including FDA alignment on a 12-month Phase 3 registrational study for EB613, the first oral anabolic tablet for osteoporosis, with study initiation planned for late 2026 and topline data expected in late 2028. The company completed an oversubscribed $275 million private placement led by BVF Partners to fund th…